Tiragolumab Biosimilar - Ultra Low Endotoxin

Human

TIGIT

>1mg/ml

Human IgG1

Anti-Human TIGIT (4E1.2) In Vivo Antibody - Low Endotoxin (ICH1219), Anti-Mouse TIGIT (1G9) In Vivo Antibody - Low Endotoxin (ICH1220), Vibostolimab Biosimilar - Research Grade (ICH5159), Tamgiblimab Biosimilar - Research Grade (ICH5279), Belrestotug Biosimilar - Research Grade (ICH5384), Dargistotug Biosimilar - Research Grade (ICH5465), Domvanalimab Biosimilar - Research Grade (ICH5486), Etigilimab Biosimilar - Research Grade (ICH5536), Lancastotug Biosimilar - Research Grade (ICH5623), Ociperlimab Biosimilar - Research Grade (ICH5722), Ralzapastotug Biosimilar - Research Grade (ICH5803), Renvistobart Biosimilar - Research Grade (ICH5816)

https://www.imgt.org/mAb-DB/

ICH3002

Q495A1

201633

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of tiragolumab, a fully human IgG1 antibody directed against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). It is manufactured as a research-grade biosimilar for laboratory use only and is not the clinical drug, nor is it intended for human or veterinary use. Built around the well-characterized TIGIT target, it is intended as a defined, reproducible tool for studying TIGIT-axis biology in vitro and in preclinical settings. Typical applications include use as a positive control or benchmarking reagent in TIGIT binding and blockade assays, as a reference antibody when screening or characterizing novel anti-TIGIT candidates, and as a starting point for ADCC or antibody-engineering workflows. The material is supplied at low endotoxin levels (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support scale-up, assay standardization, and preclinical model work. Lot-to-lot consistency and defined format make it suitable for controls and comparability studies across long-running research programs. TIGIT (T-cell immunoreceptor with Ig and ITIM domains; also called VSIG9 or VSTM3) is a co-inhibitory receptor of the immunoglobulin superfamily expressed on activated T cells, regulatory T cells, and natural killer (NK) cells. It binds the nectin-family ligands CD155 (PVR) and, with lower affinity, CD112 (PVRL2/nectin-2), competing with the co-stimulatory receptor CD226 (DNAM-1) for these ligands. Engagement of CD155 delivers inhibitory signals through TIGIT's cytoplasmic ITIM and ITT-like motifs, dampening T-cell and NK-cell activation, cytokine production, and cytotoxicity. As an immune checkpoint, TIGIT contributes to peripheral tolerance and to immune evasion in the tumor microenvironment, making the TIGIT-CD155-CD226 axis a focus of cancer immunology research.

V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3

Detects human TIGIT. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tiragolumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0033

Tiragolumab (anti-TIGIT) Biosimilar - Ultra Low Endotoxin

Q: Why choose the ultra-low-endotoxin Tiragolumab biosimilar?

A: The ultra-low-endotoxin format minimises endotoxin-driven background, making it well suited to sensitive in vivo and functional studies.

Q: Can I order the Tiragolumab biosimilar in bulk?

A: Yes — it is manufactured in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: What does the Tiragolumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Tiragolumab that binds human TIGIT for research use only (RUO).